UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000061690 |
|---|---|
| Receipt number | R000069940 |
| Scientific Title | Clinical Trial on Leucine Requirement in Japanese Elderly Men Using the Indicator Amino Acid Oxidation (IAAO) Method |
| Date of disclosure of the study information | 2026/05/26 |
| Last modified on | 2026/04/28 11:50:49 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical Trial on Leucine Requirement in Japanese Elderly Men Using the Indicator Amino Acid Oxidation (IAAO) Method
Acronym
Clinical Trial on Leucine Requirement in Japanese Elderly Men Using the Indicator Amino Acid Oxidation (IAAO) Method
Scientific Title
Clinical Trial on Leucine Requirement in Japanese Elderly Men Using the Indicator Amino Acid Oxidation (IAAO) Method
Scientific Title:Acronym
Clinical Trial on Leucine Requirement in Japanese Elderly Men Using the Indicator Amino Acid Oxidation (IAAO) Method
Region
| Japan |
Condition
Condition
Healthy elderly male
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the requirement of L-leucine in healthy Japanese elderly males.
Basic objectives2
Others
Basic objectives -Others
Amino acid requirement
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Expired rate of CO2 release
13CO2 enrichment in breath
13C phenylalanine enrichment in urine
Resting energy expenditure measured by indirect calorimetry
Rate of 13CO2 excretion in breath derived from oxidation of L-[1-13C]phenylalanine
Phenylalanine kinetics
Insulin
Plasma free amino acids
C-peptide
Free fatty acids
Triglycerides
Glucose
Glucagon
Serum fibroblast growth factor 21 (FGF21)
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Dose comparison
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
7
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Oral intake of one of the study foods A to G in each period.
Interventions/Control_2
Oral intake of one of the study foods A to G in each period.
Interventions/Control_3
Oral intake of one of the study foods A to G in each period.
Interventions/Control_4
Oral intake of one of the study foods A to G in each period.
Interventions/Control_5
Oral intake of one of the study foods A to G in each period.
Interventions/Control_6
Oral intake of one of the study foods A to G in each period.
Interventions/Control_7
Oral intake of one of the study foods A to G in each period.
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 65 | years-old | <= |
Age-upper limit
| 75 | years-old | > |
Gender
Male
Key inclusion criteria
1. Japanese men aged 65 to below 75 years at the time of consent acquisition.
2. Individuals who have a habit of consuming three meals per day.
3. Individuals whose body weight at the screening examination is between 50 and 80 kg.
4. Individuals with a body mass index (BMI) of 18.5 kg/m2 or higher and less than 30.0 kg/m2.
5. Individuals who are able to give informed consent to participate in this study after receiving a detailed explanation of the protocol and understanding its contents.
Key exclusion criteria
1. Individuals who are aware of a weight change of more than 5 kg in the month prior to obtaining consent.
2. Individuals with excessive alcohol intake.
3. Individuals suffering from diseases that affect protein and amino acid metabolism, such as diabetes, cancer, liver disease, kidney disease, HIV, etc.
4. Individuals with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs.
5. Individuals with allergies to medications and/or food.
6. Individuals with known infection with hepatitis B or C virus, HIV, or syphilis, or those who test positive for these infections at screening.
7. Individuals who donated blood or component (200 mL) within the last 1 months.
8. Individuals who donated blood (400 mL) within the last 3 months.
9. Individuals who being collected in total of blood (1200 mL) within the last 12 months and in this study.
10. Individuals deemed unsuitable for participation in the trial by the principal investigator or sub-investigator.
Target sample size
7
Research contact person
Name of lead principal investigator
| 1st name | Manato |
| Middle name | |
| Last name | Ebina |
Organization
The International Council on Amino Acid Science
Division name
Secretariat
Zip code
100-0003
Address
c/o MAINICHI ACADEMIC FORUN, Inc. Palace side Building 1-1-1 Hitotsubashi, Chiyoda-ku Tokyo
TEL
03-6267-4550
secretariat01@e-icaas.org
Public contact
Name of contact person
| 1st name | Masanori |
| Middle name | |
| Last name | Numa |
Organization
CPCC Company Limited
Division name
Clinical Planning Department
Zip code
103-0021
Address
4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo, Japan
TEL
03-6225-9001
Homepage URL
cpcc-contact@cpcc.co.jp
Sponsor or person
Institute
CPCC Company Limited
Institute
Department
Personal name
Funding Source
Organization
The International Council on Amino Acid Science
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
National Institutes of Biomedical Innovation, Health and Nutrition
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
Address
2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
Tel
03-6225-9005
IRB@cpcc.co.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 05 | Month | 26 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2026 | Year | 04 | Month | 22 | Day |
Date of IRB
| 2026 | Year | 04 | Month | 17 | Day |
Anticipated trial start date
| 2026 | Year | 05 | Month | 27 | Day |
Last follow-up date
| 2026 | Year | 09 | Month | 02 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 05 | Month | 26 | Day |
Last modified on
| 2026 | Year | 04 | Month | 28 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000069940
